Boyd Watterson Asset Management LLC OH Increases Stake in Johnson & Johnson (NYSE:JNJ)

Boyd Watterson Asset Management LLC OH grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 24.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 21,304 shares of the company's stock after acquiring an additional 4,227 shares during the period. Johnson & Johnson comprises 1.1% of Boyd Watterson Asset Management LLC OH's holdings, making the stock its 23rd largest holding. Boyd Watterson Asset Management LLC OH's holdings in Johnson & Johnson were worth $3,533,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC grew its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. Segall Bryant & Hamill LLC grew its holdings in shares of Johnson & Johnson by 1.0% during the fourth quarter. Segall Bryant & Hamill LLC now owns 36,670 shares of the company's stock valued at $5,303,000 after buying an additional 367 shares during the last quarter. Modern Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 35.6% during the fourth quarter. Modern Wealth Management LLC now owns 33,386 shares of the company's stock valued at $5,149,000 after buying an additional 8,769 shares during the last quarter. Finally, Prospect Financial Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $409,000. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. UBS Group boosted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Bank of America boosted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Barclays boosted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $1.27 during midday trading on Friday, hitting $168.29. The company's stock had a trading volume of 6,199,690 shares, compared to its average volume of 8,375,731. The stock has a fifty day moving average price of $156.08 and a 200 day moving average price of $155.78. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $404.92 billion, a price-to-earnings ratio of 18.00, a P/E/G ratio of 2.16 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.09%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.